Hematopoietic inhibiting factor containing compositions
Patent 5711881 Issued on January 27, 1998. Estimated Expiration Date: 
January 27, 2015. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
January 27, 2015. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.Patent ReferencesHemodialysis method and membrane Patent #: 4925534 InventorsAssigneeApplicationNo. 284477 filed on 10/06/1994US Classes:210/500.21, Semipermeable membrane210/500.22, Isotropically pored210/500.23, Hollow fiber or cylinder210/500.27, Organic210/500.3, Cellulose acetate210/500.35, Acrylate210/500.41, Sulfone210/500.43, Acrylonitrile210/646, Hemodialysis424/529, Blood530/380Blood proteins or globulins, e.g., proteoglycans, platelet factor 4, thyroglobulin, thyroxine, etc.ExaminersPrimary: Lilling, Herbert J.Attorney, Agent or FirmInternational ClassesA61M 001/16B01D 013/00 Foreign Application Priority Data1992-04-12 JPAbstractThe present invention relates to hematopoietic inhibiting factor-containing compositions which inhibit colony formation of CFU-E, comprising a substance obtained in the fraction eluting at exclusion limit by gel filtration using a gel having maximum molecular weight fractionation of not less than 200,000 and not more than 1,500,000, of a dialysate of blood which is obtained with a dialysis membrane having albumin sieving coefficient of not less than 0.01, followed by concentration with a membrane having molecular weight fractionation of not more than 5,000, and hematopoietic inhibiting factor-containing compositions which inhibit colony formation of CFU-E can be obtained. It further relates to a process of treating blood in which AI component is so removed as to satisfy AI/AAࣙ1/50, wherein AI is the height of the absorbancy value of the hematopoietic inhibiting factor-containing compositions and AA is the height of the maximum absorbancy value in a gel filtration pattern of solutes of the dialysate expressed in terms of the absorbancy at 280 nm, and to a dialysis membrane which satisfies AI/AAࣙ1/50. It further relates to drug compositions and a therapeutic agent for erythrocytosis, containing such hematopoietic inhibiting factor as the active ingredient. |
| ||||||||||||||
